Abstract:Objective To study the effect of intravitreal injection of Compaqip combined with 532 nm laser retinal photocoagulation in patients with diabetic retinopathy (DR). Methods A total of 117 patients with DR from January 2016 to June 2018 were selected and divided into experimental group (n=59) and control group (n=58) according to different treatment methods.The 532 nm laser retinal photocoagulation was conducted in control group,and the intravitreal injection of Compaqip was performed in experimental group based on 532 nm laser retinal photocoagulation.The clinical efficacy,complications,best corrected visual acuity (BCVA) before and after treatment,retinal thickness,levels of serum vascular endothelial growth factor (VEGF) and fibroblast growth factor (bFGF),oxidative stress response ［serum levels of malondialdehyde (MDA),reactive oxygen species (ROS),lipid hydroperoxides (LHP)］ were compared between two groups. Results The total effective rate in experimental group was significantly higher than that in control group (93.22% vs 79.31%,P<0.05);BCVA and retinal thickness were significantly improved at 1-,3- month postoperatively in both groups and were better in experimental group than those in control group (all P<0.05).One month after treatment,the levels of serum VEGF and bFGF significantly decreased in two groups and were statistically lower in experimental group than those in control group (all P<0.05);the levels of serum MDA,ROS and LHP in experimental group were significantly lower than those in control group (all P<0.05).There was no statistical difference in the incidence of complications between experimental group and control group ( 6.78% vs 3.45%,P>0.05). Conclusion In the treatment of diabetic retinopathy,intravitreal injection of Compaqip combined with 532 nm laser retinal photocoagulation can further reduce serum VEGF and bFGF levels,alleviate oxidative stress,improve the curative efficacy of DR and visual function with high safety.